Adora Trials

I generally favor the adjuvant TKI's. Osamir and NIB is approved here. I've already adopted Alk inhibitors here. The other targeted agents, BRAF, MET, I think the therapeutic windows just smaller because they're more toxic. This is a question from the audience. Do you offer them ear-back immunotherapy afterwards? So I think this is something that is very much debated at my institution. If someone has a lot of residual tumor,. Someone has a path to CR, but I'm not giving it right now. There are a couple questions. One is using the targeted agents in the adjUvant setting; if you decide to do that, how